Literature DB >> 26639197

Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy.

Indu R Ramachandran1, Thomas Condamine2, Cindy Lin3, Sarah E Herlihy3, Alfred Garfall4, Dan T Vogl4, Dmitry I Gabrilovich2, Yulia Nefedova5.   

Abstract

Multiple myeloma (MM) is an incurable cancer of plasma cells localized preferentially in the bone marrow (BM). Resistance to chemotherapy represents one of the main challenges in MM management. BM microenvironment is known to play a critical role in protection of MM cells from chemotherapeutics; however, mechanisms responsible for this effect are largely unknown. Development of MM is associated with accumulation of myeloid-derived suppressor cells (MDSCs) mostly represented by pathologically activated relatively immature polymorphonuclear neutrophils (PMN-MDSCs). Here, we investigated whether PMN-MDSCs are responsible for BM microenvironment-mediated MM chemoresistance. Using in vivo mouse models allowing manipulation of myeloid cell number, we demonstrated a critical role for myeloid cells in MM growth and chemoresistance. PMN-MDSCs isolated from MM-bearing host are immunosuppressive and thus, functionally distinct from their counterpart in tumor-free host neutrophils. We found, however, that both PMN-MDSCs and neutrophils equally promote MM survival from doxorubicin and melphalan and that this effect is mediated by soluble factors rather than direct cell-cell contact. Our data indicate that targeting PMN-MDSCs would enhance chemotherapy efficacy in MM.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Chemoresistance; Multiple myeloma; Myeloid-derived suppressor cells; Neutrophils

Mesh:

Substances:

Year:  2015        PMID: 26639197      PMCID: PMC4919899          DOI: 10.1016/j.canlet.2015.10.040

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  30 in total

1.  Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA.

Authors:  F Liu; Y Song; D Liu
Journal:  Gene Ther       Date:  1999-07       Impact factor: 5.250

2.  Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line.

Authors:  G V Dedoussis; A Mouzaki; M Theodoropoulou; P Menounos; M C Kyrtsonis; A Karameris; A Maniatis
Journal:  Exp Cell Res       Date:  1999-06-15       Impact factor: 3.905

3.  Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.

Authors:  Yue Wang; Xiu Long Niu; Ye Qu; Jian Wu; Ya Qin Zhu; Wei Jia Sun; Ling Zhi Li
Journal:  Cancer Lett       Date:  2010-03-16       Impact factor: 8.679

4.  ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.

Authors:  Thomas Condamine; Vinit Kumar; Indu R Ramachandran; Je-In Youn; Esteban Celis; Niklas Finnberg; Wafik S El-Deiry; Rafael Winograd; Robert H Vonderheide; Nickolas R English; Stella C Knight; Hideo Yagita; Judith C McCaffrey; Scott Antonia; Neil Hockstein; Robert Witt; Gregory Masters; Thomas Bauer; Dmitry I Gabrilovich
Journal:  J Clin Invest       Date:  2014-05-01       Impact factor: 14.808

5.  CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment.

Authors:  Jayakumar R Nair; Louise M Carlson; Chandana Koorella; Cheryl H Rozanski; Gerald E Byrne; P Leif Bergsagel; John P Shaughnessy; Lawrence H Boise; Asher Chanan-Khan; Kelvin P Lee
Journal:  J Immunol       Date:  2011-06-29       Impact factor: 5.422

6.  Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.

Authors:  Güllü Topal Görgün; Gregory Whitehill; Jennifer L Anderson; Teru Hideshima; Craig Maguire; Jacob Laubach; Noopur Raje; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

7.  Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.

Authors:  Yuhuan Zheng; Zhen Cai; Siqing Wang; Xiang Zhang; Jianfei Qian; Sungyoul Hong; Haiyan Li; Michael Wang; Jing Yang; Qing Yi
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

8.  Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.

Authors:  Indu R Ramachandran; Anna Martner; Alexandra Pisklakova; Thomas Condamine; Tess Chase; Thomas Vogl; Johannes Roth; Dmitry Gabrilovich; Yulia Nefedova
Journal:  J Immunol       Date:  2013-03-04       Impact factor: 5.422

9.  Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

Authors:  Dharminder Chauhan; Ajita V Singh; Mohan Brahmandam; Ruben Carrasco; Madhavi Bandi; Teru Hideshima; Giada Bianchi; Klaus Podar; Yu-Tzu Tai; Constantine Mitsiades; Noopur Raje; David L Jaye; Shaji K Kumar; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Cancer Cell       Date:  2009-10-06       Impact factor: 31.743

10.  Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.

Authors:  T Bachelot; I Ray-Coquard; C Menetrier-Caux; M Rastkha; A Duc; J-Y Blay
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

View more
  29 in total

1.  Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.

Authors:  Vinit Kumar; Laxminarasimha Donthireddy; Douglas Marvel; Thomas Condamine; Fang Wang; Sergio Lavilla-Alonso; Ayumi Hashimoto; Prashanthi Vonteddu; Reeti Behera; Marlee A Goins; Charles Mulligan; Brian Nam; Neil Hockstein; Fred Denstman; Shanti Shakamuri; David W Speicher; Ashani T Weeraratna; Timothy Chao; Robert H Vonderheide; Lucia R Languino; Peter Ordentlich; Qin Liu; Xiaowei Xu; Albert Lo; Ellen Puré; Chunsheng Zhang; Andrey Loboda; Manuel A Sepulveda; Linda A Snyder; Dmitry I Gabrilovich
Journal:  Cancer Cell       Date:  2017-11-13       Impact factor: 31.743

Review 2.  Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.

Authors:  Fotis Asimakopoulos; Chelsea Hope; Michael G Johnson; Adam Pagenkopf; Kimberly Gromek; Bradley Nagel
Journal:  J Leukoc Biol       Date:  2017-03-02       Impact factor: 4.962

Review 3.  Myeloid-Derived Suppressor Cells.

Authors:  Dmitry I Gabrilovich
Journal:  Cancer Immunol Res       Date:  2017-01       Impact factor: 11.151

Review 4.  Mechanistic insights into the interplays between neutrophils and other immune cells in cancer development and progression.

Authors:  Zimam Mahmud; Atiqur Rahman; Israt Dilruba Mishu; Yearul Kabir
Journal:  Cancer Metastasis Rev       Date:  2022-03-21       Impact factor: 9.237

5.  Disruption of LTBP4 Induced Activated TGFβ1, Immunosuppression Signal and Promoted Pulmonary Metastasis in Hepatocellular Carcinoma.

Authors:  Xiou Yang; Xiaojuan Ye; Liuyan Zhang; Xingguo Zhang; Peng Shu
Journal:  Onco Targets Ther       Date:  2020-07-20       Impact factor: 4.147

6.  Estrogen promotes multiple myeloma through enhancing the immunosuppressive activity of MDSC.

Authors:  Maria Ozerova; Yulia Nefedova
Journal:  Leuk Lymphoma       Date:  2019-01-02

7.  Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b/ICAM-1 binding.

Authors:  Taghreed Hirz; Eva-Laure Matera; Kamel Chettab; Lars Petter Jordheim; Doriane Mathé; Anne Evesque; Justine Esmenjaud; Gilles Salles; Charles Dumontet
Journal:  Oncotarget       Date:  2017-08-18

Review 8.  Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities.

Authors:  Cirino Botta; Francesco Mendicino; Enrica Antonia Martino; Ernesto Vigna; Domenica Ronchetti; Pierpaolo Correale; Fortunato Morabito; Antonino Neri; Massimo Gentile
Journal:  Cancers (Basel)       Date:  2021-06-28       Impact factor: 6.639

9.  The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents.

Authors:  Alessandra Romano; Nunziatina Laura Parrinello; Claudio Cerchione; Maria Letizia Consoli; Marina Parisi; Valeria Calafiore; Enrica Martino; Concetta Conticello; Francesco Di Raimondo; Giuseppe Alberto Palumbo
Journal:  Blood Cancer J       Date:  2017-12-15       Impact factor: 11.037

Review 10.  The role of tumor microenvironment in therapeutic resistance.

Authors:  Beomseok Son; Sungmin Lee; HyeSook Youn; EunGi Kim; Wanyeon Kim; BuHyun Youn
Journal:  Oncotarget       Date:  2017-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.